COTA, Baptist Health South Florida, PreciseDx collaborate on AI-based test for IBC recurrence

New payment code and Medicare payment implemented for AI cancer imaging device

Avenda Health, an AI healthcare company, announced the Centers for Medicare & Medicaid Services has assigned a national payment rate for the company’s innovative prostate cancer mapping technology, Unfold AI.

July 26, 2024

Vol.50 No.30

Clinical Roundup

AI enhances physicians’ ability to identify extent of prostate cancer with 84% accuracy

Unfold AI is better at identifying cancer margins in the prostate than physicians identifying margins by sight, according to a new study. This AI improves accuracy from 67% to 84%, giving physicians more clarity and treatment planning, allowing them to better recommend therapies tailored to each patient.

July 19, 2024

Vol.50 No.29

Clinical Roundup

Electronic prompt for surgeons may reduce breast cancer overtreatment

University of Pittsburgh and UPMC Hillman Cancer Center researchers have developed a novel prompt, or ‘nudge,’ embedded in the electronic health record that flags, for treating surgeons, older patients with early-stage breast cancer who may be at risk for unnecessary lymph node surgery.

July 19, 2024

Vol.50 No.29

In Brief

Mark Burkard named director of UI Health Care Holden Comprehensive Cancer Center

Mark Burkard was named director of University of Iowa Health Care Holden Comprehensive Cancer Center.

July 12, 2024

Vol.50 No.28

Clinical Roundup

Chemotherapy disrupts gut microbiome in patients with breast cancer

Chemotherapy is known to cause behavioral side effects, including cognitive decline. Notably, the gut microbiome communicates with the brain to affect behavior, including cognition.

July 12, 2024

Vol.50 No.28

Clinical Roundup

Exscientia builds AWS AI-powered platform to advance drug discovery

Exscientia plc announced it will be expanding its work with Amazon Web Services to use the cloud provider’s artificial intelligence and machine learning services to power its platform for end-to-end drug discovery and automation.

July 12, 2024

Vol.50 No.28

COTA, Baptist Health South Florida, PreciseDx collaborate on AI-based test for IBC recurrence

YOU MAY BE INTERESTED IN

New payment code and Medicare payment implemented for AI cancer imaging device

AI enhances physicians’ ability to identify extent of prostate cancer with 84% accuracy

Electronic prompt for surgeons may reduce breast cancer overtreatment

Mark Burkard named director of UI Health Care Holden Comprehensive Cancer Center

Chemotherapy disrupts gut microbiome in patients with breast cancer

Exscientia builds AWS AI-powered platform to advance drug discovery

Renew today!

Subscriber content

Login